Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Russian agency: Russia will conduct a nuclear test if the US does
Al-Nakhalah: We are the rightful owners, and we must fight to retrieve our rights
Al-Nakhalah: The enemy and its allies must know that we can never surrender to their terms and diktats after all the sacrifices made
Al-Nakhalah: The prisoner exchange clause can be completed in the next few days, and thus we will have pulled the [explosion] fuse and removed the enemy's justifications for aggression
Al-Nakhalah: The Resistance has expressed its willingness to negotiate on the basis that there are items that can be dealt with positively, the first of which is the prisoner exchange item
Al-Nakhalah: Trump's plan entails the Palestinian people's declaration of complete surrender to the enemy
PIJ Secretary-General, Ziyad al-Nakhalah, in an address aired on Al Mayadeen: The Resistance is engaging in a fierce negotiating battle under the so-called Trump plan
Russian Federation Council approves joint military cooperation agreement with Cuba
Al-Nunu: Today, the lists of prisoners required to be released, the agreed-upon criteria and numbers, were exchanged
Al-Nunu from Sharm el-Sheikh: Negotiations focused on mechanisms for implementing an end to the war, the withdrawal of occupation forces from the Gaza Strip, and the exchange of prisoners

CAR T Cell Therapy reaches beyond cancer

  • By Al Mayadeen English
  • Source: Agencies
  • 24 Nov 2022 18:32
  • 1 Shares
4 Min Read

A Penn Medicine CAR T pioneer and a doctoral student in Cell and Molecular Biology discuss the development and progress in treating certain B cell leukemia, lymphoma, and other blood cancers.

  • x
  • CAR T Cell Therapy Reaches Beyond Cancer (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)
    Researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)

Chimeric antigen receptor cells (CAR T), or engineered immune cells, have revealed the ability of personalized immunotherapies to fight blood cancers. Now, researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this progress in a commentary published today in Cell.

"We've always known that in principle, CAR T therapies could have broad applications, and it's very encouraging to see early evidence that this promise is now being realized," said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn's Abramson Cancer Center.

Read: Immunotherapy treatment "cures" 2 cancer patients

T cells are among the immune system's most powerful weapons. They can bind to and kill the cells they see as valid targets, including cells infected by viruses. CAR T cells are T cells that have been redirected to effectively kill specifically defined cell types, through genetic engineering.

How are CAR T therapies created?

The cells of each patient are what make CAR T therapies; they are collected from the patient's blood and engineered and multiplied in a lab before they are re-infused into the patient as a "living drug."

The first CAR T therapy, Kymriah, was developed by June and his team at Penn Medicine. It was approved by the Food and Drug Administration in 2017. There are now six FDA-approved CAR T cell therapies in the United States for six different cancers. The therapies have created a revolution in the treatment of certain B cell leukemia, lymphoma, and other blood cancers. Many patients who had little hope have now been put into long-term remission.

Since the beginning of the research, experts believed that T cells could be engineered to fight many conditions other than B cell cancers. These potential new applications are being examined by dozens of research teams around the globe.

The commentary from Baker and June comes in response to the first significant clinical report about the success resulting from these efforts: a paper in Nature Medicine by German researchers on the CAR T therapy used to fight the autoimmune disease lupus (systemic lupus erythematosus).

Lupus, according to researchers, is an obvious choice for CAR T therapy because it, too, is driven by B cells. Thus, experimental CAR T therapies can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise and attack the patient's own organs and tissues.

In the German study, the patients, five young adults, did not benefit from standard lupus treatments. Yet, they all went into remission and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells.

What was even more noticeable is that all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients' B cells came back. They are naturally replenished from blood stem cells in the bone marrow.

June and Baker noted in their commentary that, although the German study's results should be confirmed with bigger studies and longer-term follow-up, they are significantly promising. They suggest that lupus could turn out to be an easier CAR T target than B-cell cancers.

"Disease-driving B cells are much less numerous in lupus," Baker said. "Thus, effective CAR T treatment of this autoimmune disease may require a much lower dose that greatly reduces the problem of immunological side-effects."

  • Cell Therapy
  • Car T
  • Cancer
  • Engineered immune cells

Most Read

Tucker Carlson speaks at a memorial for Charlie Kirk, Sunday, September 21, 2025, at State Farm Stadium in Glendale, Arizona (AP)

Tucker Carlson: Israeli officers gave orders on Iran inside Pentagon

  • Politics
  • 2 Oct 2025
A Hamas fighter in combat fatigues stands before the ceremony for the handover of Israeli captives to the Red Cross in Nuseirat, central Gaza Strip, Saturday, February 22, 2025 (AP)

Hamas responds to Trump plan, backs Gaza withdrawal, exchange

  • Politics
  • 3 Oct 2025
ap

'Israel' pays influencers $7K per post to whitewash Gaza genocide

  • Politics
  • 1 Oct 2025
Mossad’s secret role in Aldo Moro’s 1978 murder revealed

Mossad’s secret role in Aldo Moro’s 1978 murder exposed

  • Politics
  • 5 Oct 2025

Coverage

All
War on Gaza

Read Next

All
Retired Israeli General Brik says Israel has reached point of no return.
Politics

Retired Israeli General Brik: 'Israel has reached point of no return'

Depleted by foreign wars, US seeks to re-arm for another confrontation
Politics

Depleted by foreign wars, US seeks to re-arm for another confrontation

Gaza’s newborns gasp for life as hospitals collapse amid Israeli war
Health

Gaza newborns gasp for life, share oxygen masks amid collapsed system

UK arms exports to 'Israel' reach record high despite ban calls
Politics

UK arms exports to 'Israel' reach record high despite ban calls

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS